[go: up one dir, main page]

WO2008086538A1 - Branched chain amino acid chelate - Google Patents

Branched chain amino acid chelate Download PDF

Info

Publication number
WO2008086538A1
WO2008086538A1 PCT/US2008/050974 US2008050974W WO2008086538A1 WO 2008086538 A1 WO2008086538 A1 WO 2008086538A1 US 2008050974 W US2008050974 W US 2008050974W WO 2008086538 A1 WO2008086538 A1 WO 2008086538A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
mineral
branched
percent
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/050974
Other languages
French (fr)
Inventor
Eric Bastian
Brent Hagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glanbia PLC
Original Assignee
Glanbia PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glanbia PLC filed Critical Glanbia PLC
Publication of WO2008086538A1 publication Critical patent/WO2008086538A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23JPROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A23J1/205Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/19Dairy proteins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to nutritional compositions. More specifically, the invention relates to dietary supplements for increasing branched-chain amino acid delivery and for methods of providing increased levels of branch-chain amino acids utilizing dietary supplements, Background of the Invention
  • Mineral absorption generally occurs in the small intestine via a combination of active, or transcellular, absorption and passive, or paracellular, absorption.
  • nutritional supplementation of foods with minerals has become common and a primary method for providing minerals in foods and in supplements is to provide them as chelates formed with amino acids or peptides to improve absorption of the mineral.
  • Minerals provided in the chelated form are more available for absorption. Studies in animals, for example, have demonstrated that chelated minerals provided in the diet result in higher mineral absorption and utilization.
  • AAFCO American Association of Feed Control Officials
  • Patent application publication number 2002/0058088 (Henry et al.) describes chelates of alpha- amino acids for producing color stable iron-fortified compositions, where the ligand to metal ratio is at least 2:1.
  • U.S. Patent application publication number 2005/0239763 (Motyka et al.) describes a metal amino acid chelate composition having an amino acid to metal molar ratio of from about 1 :1 to 4:1 , as does U.S. Patent application publication number 2005/0239750 (Motyka et al.).
  • U.S. Patent application publication number 2003/0206969 discloses an iron/amino acid chelate having a metal: ligand ratio of 1 :1-3.
  • Amino acids are generally considered to be efficiently absorbed in the normal human or animal intestine, but not all ingested amino acids are well-absorbed.
  • BSA bovine serum albumin
  • the amino acids alanine, phenylalanine, arginine, leucine, methionine, and tyrosine were absorbed at a rate of 50% or more (e.g., 86% for methionine).
  • Other amino acids, such as cystine (3%) were absorbed at much lower rates.
  • BCAAs branched- chain amino acids
  • Amino acid supplementation is generally accomplished by ingesting higher-protein foods, isolated proteins and/or amino acids, or hydrolyzed proteins.
  • Aqueous formulations of the branched-chain amino acids which would provide a formulation that could be more easily consumed by individuals who might particularly benefit from BCAA supplementation, are difficult to prepare because BCAAs have non-polar side groups and are hydrophobic.
  • the present invention relates to a mineral branched-chain amino acid chelate.
  • the invention relates to a leucine chelate such as calcium leucinate.
  • the mineral can comprise a mono- or divalent cation such as calcium, magnesium, potassium or zinc and the branched-chain amino acid can comprise isoleucine or valine.
  • One aspect of the invention relates to methods of incorporating branched-chain amino acids into food or nutritional supplement products.
  • a method for incorporating branched-chain amino acids into liquid or aqueous food or supplements is provided, the method comprising providing one or more branched-chain amino acids in the form of a BCAA/mineral chelate.
  • the invention also relates to methods of use of BCAA chelates to provide increased levels of BCAAs to a human or animal subject via food and/or nutritional supplementation.
  • nutritional supplementation may comprise a nutritional supplement product such as a powder, capsule, tablet, or nutritional drink, for example.
  • nutritional supplementation may comprise supplementation of a food or feed product.
  • composition of the invention comprises a combination of one or more BCAA/mineral chelates and a whey protein product such as whey protein concentrate or whey protein isolate.
  • the invention is a composition comprising a mineral/branched- chain amino acid chelate formed by chelating a mineral such as calcium or magnesium using leucine or other branched chain amino acid as the chelating amino acid.
  • the composition is formed by reacting a mineral source, such as, but not limited to, calcium or magnesium carbonate, with free leucine, or other branched chain amino acid (BCAA), to form, in one embodiment, calcium leucinate.
  • a mineral source such as, but not limited to, calcium or magnesium carbonate
  • BCAA free leucine, or other branched chain amino acid
  • the mineral can comprise, for example, calcium, magnesium, potassium or zinc and the branched-chain amino acid can comprise leucine, isoleucine or valine.
  • the mineral moiety of a composition of the invention can be provided by, for example, calcium chloride, calcium carbonate, calcium citrate, calcium lactate, calcium gluconate, calcium phosphate, milk calcium, coral calcium, egg shell calcium, calcium hydroxide, calcium sulfate, magnesium chloride, magnesium carbonate, magnesium citrate, magnesium oxide, magnesium phosphate, magnesium hydroxide, magnesium lactate, magnesium sulfate, zinc sulfate, zinc citrate, zinc gluconate, zinc picolinate, zinc chloride, zinc oxide and/or other calcium, magnesium, zinc, or potassium salts.
  • Other appropriate sources of mono- or divalent cations such as calcium, magnesium, zinc, or potassium, for example, are known to those of skill in the art and may be used in the present composition.
  • BCAA/mineral chelates of the invention provide an amino acid that is more easily incorporated into the final product.
  • compositions of the present invention may comprise from about 75 to about 80 percent leucine and from about 10 to about 12 percent calcium.
  • a calcium leucinate composition comprises a calcium to leucine molar ratio of 1 to 2.
  • compositions can comprise, by weight, from about 40% to about 90% amino acid and from about 5 to about 60 percent mineral.
  • compositions may comprise from about 10 to about 40 percent mineral in combination with from about 60 to about 90% amino acid.
  • Compositions may also comprise from about 75 to about 80 percent amino acid and from about 20 to about 25% percent mineral.
  • compositions of the invention may be incorporated into formulations including, but not limited to, a full range of beverages, bars, foods, animal feeds, powders, drinks, or provided as supplement tablets, caplets, capsules, or other formulations for human or animal use.
  • Compositions described by the invention may be used to provide increased availability of branched-chain amino acids, which are known to play important roles in a variety of metabolic processes.
  • Branched- chain amino acids L-leucine (2-amino-4-methylvaleric acid; alpha- aminoisocaproic acid; (S)-2-amino-4-methylpentanoic acid, chemical formula C6H13NO2), L-valine (2-aminoisovaleric acid; 2-amino-3-methylbutyric acid; alpha-aminoisovaleric acid; (S)-2-amino-3-methylbutanoic acid; chemical formula C5H11 NO2); and L-isoleucine (2-amino-3-methylvaleric acid; alpha- amino-beta-methylvaleric acid; (2S,3S)-2-amino-3-methyl pentanoic acid; chemical formula C6H13NO2) play important roles, for example, in modulation of protein turnover and recovery from mental fatigue.
  • leucine has been shown to be a specific modulator of protein turnover (Bevington, A. et al. Eur. J. Clin. Invest. (2001 ) 31 (6): 497-503) and branched-chain amino acids have been shown to decrease muscle proteolysis via inhibition of lysosomal proteolysis (Busquets, S. et al. J. Cell Physiol. (2000) 184(3): 380-
  • compositions of the present invention provides a method for increasing the availability of BCAAs in food and nutritional supplements and related products and providing a therapeutic benefit for building and/or maintaining muscle tissue where loss of muscle tissue is associated with conditions that include, but are not limited to, stroke, spinal cord injury, osteoarthritis, rheumatoid arthritis, prolonged corticosteroid therapy, diabetic neuropathy, burns, amyotrophic lateral sclerosis (ALS), Buillain-Barre Syndrome, Muscular Dystrophy, sarcopenia associated with aging, and muscle tissue loss associated with weightlessness in astronauts.
  • ALS amyotrophic lateral sclerosis
  • Administration may be accomplished by oral or enteral means, and compositions may include tablets, caplets, gelatin capsules, powders, nutritional foods, nutritional drinks, enteral feeding formulations, and the like, comprising at least one BCAA/mineral chelate of the invention.
  • the invention provides nutritional therapies for individuals having the aforementioned conditions, as well as for athletes desiring to build and/or maintain muscle mass and improve muscle strength. The invention may also provide a nutritional means to decrease mental fatigue.
  • compositions of the invention may be provided as tablets, caplets, gelatin capsules, chewable tablets, a supplemented drink, nutrition bar, or other formulation to provide at least one BCAA/mineral chelate to an individual to decrease mental fatigue following, for example, strenuous exercise or physically- demanding work.
  • BCAA/mineral chelates of the invention may also be administered in a method of the invention to increase BCAA absorption and decrease central fatigue after exercise.
  • Table 1 lists ingredients comprising an example of a composition comprising a powdered formulation to provide a nutritional drink as provided by the invention.
  • WPC whey protein concentrate
  • WPI Whey protein isolate
  • Chelated leucine may be present in such a composition from about 0.1 gram to about 2 grams, and crystalline fructose may be present from about 10 grams to about 20 grams.
  • compositions of the invention may comprise at least about about 0.1 grams of leucine, isoleucine, valine, or combinations thereof, and preferably will be formulated to provide at least about 3 grams daily of leucine, isoleucine, valine, or combinations thereof.
  • Compositions may be provided for occasional or for regular use, with regular use being preferred. Regular use may include daily, twice-daily, every other day, or other regimens, for example. For improved effect, administration of at least 3 grams of leucine per day, for example, may be preferred.
  • compositions of the invention providing, for example, BCAA/mineral chelates for use in aqueous formulations, powders dispersed in aqueous formulations, or similar compositions, increase availability of BCAAs to human or animal subjects to whom they are provided or administered.
  • a method for providing branched-chain amino acids in a liquid beverage comprising forming a branched-chain amino acid chelate and adding the chelate to the beverage.
  • the inventors attempted to incorporate free leucine and microencapsulated free leucine into beverages and found both products difficult to use and difficult to disperse.
  • the microencapsulated leucine produced a turbid, cloudy solution, indicative of non-dissolving particulates.
  • Free leucine showed a separation phenomenon in aqueous solution.
  • a BCAA/mineral chelate of the invention was utilized, however, the chelated leucine product was much more easily dispersed and did not separate or increase turbidity of aqueous systems.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions are disclosed comprising mineral/branched-chain amino acid chelates such as, for example, calcium leucinate, for increasing absorption of the branched-amino acid in a human or animal subject. Methods are also provided for using the compositions to increase branched-chain amino acid absorption to increase or maintain muscle mass in athletes or in individuals having diseases such as ALS, muscular dystrophy, sarcopenia associated with aging, or muscle atrophy associated with spinal cord injury, as well as to decrease mental fatigue.

Description

Branched Chain Amino Acid Chelate
[001 ] This application claims the benefit of priority of United States provisional patent application number 60/884,890, filed January 14, 2007. Field of the Invention
[002] The present invention relates to nutritional compositions. More specifically, the invention relates to dietary supplements for increasing branched-chain amino acid delivery and for methods of providing increased levels of branch-chain amino acids utilizing dietary supplements, Background of the Invention
[003] Mineral absorption generally occurs in the small intestine via a combination of active, or transcellular, absorption and passive, or paracellular, absorption. A variety of factors, including undesirable chelation reactions (e.g., reaction with another mineral) in the digestive system, may make dietary minerals more difficult for the body to absorb. To address this problem, nutritional supplementation of foods with minerals has become common and a primary method for providing minerals in foods and in supplements is to provide them as chelates formed with amino acids or peptides to improve absorption of the mineral. [004] Minerals provided in the chelated form are more available for absorption. Studies in animals, for example, have demonstrated that chelated minerals provided in the diet result in higher mineral absorption and utilization.
[005] The American Association of Feed Control Officials (AAFCO) defines a chelate as a product resulting from the reaction of a metal ion from a soluble metal salt with amino acids having a mole ratio of one mole of metal to one to three (preferably 2) moles of amino acids to form coordinate covalent bonds. Metal/ami no acid chelates for improving absorption of minerals have been described previously, where the metal is chelated with an alpha amino acid (e.g., glycine, lysine, etc.). For example, U.S. Patent application publication number 2002/0058088 (Henry et al.) describes chelates of alpha- amino acids for producing color stable iron-fortified compositions, where the ligand to metal ratio is at least 2:1. U.S. Patent application publication number 2005/0239763 (Motyka et al.) describes a metal amino acid chelate composition having an amino acid to metal molar ratio of from about 1 :1 to 4:1 , as does U.S. Patent application publication number 2005/0239750 (Motyka et al.). U.S. Patent application publication number 2003/0206969 discloses an iron/amino acid chelate having a metal: ligand ratio of 1 :1-3.
[006] Amino acids are generally considered to be efficiently absorbed in the normal human or animal intestine, but not all ingested amino acids are well-absorbed. For example, when pre-hydrolyzed bovine serum albumin (BSA) was perfused into the jejunum of human subjects, the amino acids alanine, phenylalanine, arginine, leucine, methionine, and tyrosine were absorbed at a rate of 50% or more (e.g., 86% for methionine). (Reicht, G. et al. (1997) Eur. J. Gastroenterol. Hepatol. 9 81 -85.) Other amino acids, such as cystine (3%) were absorbed at much lower rates. In individuals with certain diseases or conditions such as sepsis or peritonitis, those with muscle wasting disorders or cachexia related to AIDS or cancer, or older individuals in whom amino acid absorption decreases as part of the aging process, there is an even lower percentage of absorption of necessary amino acids. Certain amino acids are of particular interest because they promote protein synthesis, spare lean body mass during weight loss, decrease muscle wasting associated with aging, and promote wound healing. These are the branched- chain amino acids (BCAAs). BCAAs have received particular attention due to their effect on protein metabolism. After a meal containing protein has been ingested, studies have shown that half of the BCAAs from the meal will be absorbed and transported into the systemic circulation. (Matthews, D. (2005) J. Nutrition 135: 1580S-1584S).
[007] Amino acid supplementation is generally accomplished by ingesting higher-protein foods, isolated proteins and/or amino acids, or hydrolyzed proteins. Aqueous formulations of the branched-chain amino acids, which would provide a formulation that could be more easily consumed by individuals who might particularly benefit from BCAA supplementation, are difficult to prepare because BCAAs have non-polar side groups and are hydrophobic.
[008] What are needed are formulations containing branched-chain amino acids that make those amino acids more available to individuals in whom they may provide a benefit.
Summary of the Invention
[009] The present invention relates to a mineral branched-chain amino acid chelate. In one embodiment, the invention relates to a leucine chelate such as calcium leucinate.
[010] In alternate embodiments, the mineral can comprise a mono- or divalent cation such as calcium, magnesium, potassium or zinc and the branched-chain amino acid can comprise isoleucine or valine.
[011 ] One aspect of the invention relates to methods of incorporating branched-chain amino acids into food or nutritional supplement products. In one embodiment, a method for incorporating branched-chain amino acids into liquid or aqueous food or supplements is provided, the method comprising providing one or more branched-chain amino acids in the form of a BCAA/mineral chelate. [012] The invention also relates to methods of use of BCAA chelates to provide increased levels of BCAAs to a human or animal subject via food and/or nutritional supplementation. In one embodiment, nutritional supplementation may comprise a nutritional supplement product such as a powder, capsule, tablet, or nutritional drink, for example. In another aspect, nutritional supplementation may comprise supplementation of a food or feed product.
[013] One aspect of a composition of the invention comprises a combination of one or more BCAA/mineral chelates and a whey protein product such as whey protein concentrate or whey protein isolate.
Detailed Description
[014] The invention is a composition comprising a mineral/branched- chain amino acid chelate formed by chelating a mineral such as calcium or magnesium using leucine or other branched chain amino acid as the chelating amino acid. The composition is formed by reacting a mineral source, such as, but not limited to, calcium or magnesium carbonate, with free leucine, or other branched chain amino acid (BCAA), to form, in one embodiment, calcium leucinate. In compositions of the present invention, the mineral can comprise, for example, calcium, magnesium, potassium or zinc and the branched-chain amino acid can comprise leucine, isoleucine or valine. [015] The mineral moiety of a composition of the invention can be provided by, for example, calcium chloride, calcium carbonate, calcium citrate, calcium lactate, calcium gluconate, calcium phosphate, milk calcium, coral calcium, egg shell calcium, calcium hydroxide, calcium sulfate, magnesium chloride, magnesium carbonate, magnesium citrate, magnesium oxide, magnesium phosphate, magnesium hydroxide, magnesium lactate, magnesium sulfate, zinc sulfate, zinc citrate, zinc gluconate, zinc picolinate, zinc chloride, zinc oxide and/or other calcium, magnesium, zinc, or potassium salts. Other appropriate sources of mono- or divalent cations such as calcium, magnesium, zinc, or potassium, for example, are known to those of skill in the art and may be used in the present composition.
[016] Although calcium glycinate compositions have been previously described for the purpose of utilizing the amino acid to increase absorption of the calcium mineral, the inventors are not aware that a mineral/branched- chain amino acid chelate comprising calcium, magnesium, potassium or zinc, or the use of such a composition has been utilized to improve the ease of formulation of compositions comprising branched-chain amino acids. Previously described glycinate compositions have been formed for the purpose of utilizing the amino acid moiety to increase absorption of the mineral. The present invention utilizes the mineral in a BCAA chelate to further increase ease of incorporation of the BCAA moiety of the chelate into a food or nutritional supplement product and to facilitate delivery of BCAAs to a human or animal subject. Especially where aqueous formulations are desired, or aqueous formulations are utilized in the preparation of more non- aqueous products, such as feeds, nutritional bars, and other more solid compositions, BCAA/mineral chelates of the invention provide an amino acid that is more easily incorporated into the final product.
[017] In embodiments of the invention comprising calcium, the calcium may be provided in a variety of forms including, for example, a dairy mineral composition, calcium chloride or calcium hydroxide. For calcium leucinate compositions, for example, compositions of the present invention may comprise from about 75 to about 80 percent leucine and from about 10 to about 12 percent calcium. In one embodiment, a calcium leucinate composition comprises a calcium to leucine molar ratio of 1 to 2. [018] Depending upon the particular mineral/amino acid combination desired, compositions can comprise, by weight, from about 40% to about 90% amino acid and from about 5 to about 60 percent mineral. In some embodiments, compositions may comprise from about 10 to about 40 percent mineral in combination with from about 60 to about 90% amino acid. Compositions may also comprise from about 75 to about 80 percent amino acid and from about 20 to about 25% percent mineral.
[019] Compositions of the invention may be incorporated into formulations including, but not limited to, a full range of beverages, bars, foods, animal feeds, powders, drinks, or provided as supplement tablets, caplets, capsules, or other formulations for human or animal use.
[020] Compositions described by the invention may be used to provide increased availability of branched-chain amino acids, which are known to play important roles in a variety of metabolic processes. Branched- chain amino acids L-leucine (2-amino-4-methylvaleric acid; alpha- aminoisocaproic acid; (S)-2-amino-4-methylpentanoic acid, chemical formula C6H13NO2), L-valine (2-aminoisovaleric acid; 2-amino-3-methylbutyric acid; alpha-aminoisovaleric acid; (S)-2-amino-3-methylbutanoic acid; chemical formula C5H11 NO2); and L-isoleucine (2-amino-3-methylvaleric acid; alpha- amino-beta-methylvaleric acid; (2S,3S)-2-amino-3-methyl pentanoic acid; chemical formula C6H13NO2) play important roles, for example, in modulation of protein turnover and recovery from mental fatigue. For example, leucine has been shown to be a specific modulator of protein turnover (Bevington, A. et al. Eur. J. Clin. Invest. (2001 ) 31 (6): 497-503) and branched-chain amino acids have been shown to decrease muscle proteolysis via inhibition of lysosomal proteolysis (Busquets, S. et al. J. Cell Physiol. (2000) 184(3): 380-
4).
[021 ] Branched-chain amino acids have been demonstrated to be significantly decreased after mental fatigue (J. Neural Transm. (2006) Dec. 11 , 2006 e-publication) and administration of BCAAs was recently shown to decrease central fatigue after exercise (J. Nutr. (2006) 136: 544S-547S).
[022] Administration of compositions of the present invention provides a method for increasing the availability of BCAAs in food and nutritional supplements and related products and providing a therapeutic benefit for building and/or maintaining muscle tissue where loss of muscle tissue is associated with conditions that include, but are not limited to, stroke, spinal cord injury, osteoarthritis, rheumatoid arthritis, prolonged corticosteroid therapy, diabetic neuropathy, burns, amyotrophic lateral sclerosis (ALS), Buillain-Barre Syndrome, Muscular Dystrophy, sarcopenia associated with aging, and muscle tissue loss associated with weightlessness in astronauts. [023] Administration may be accomplished by oral or enteral means, and compositions may include tablets, caplets, gelatin capsules, powders, nutritional foods, nutritional drinks, enteral feeding formulations, and the like, comprising at least one BCAA/mineral chelate of the invention. [024] The invention provides nutritional therapies for individuals having the aforementioned conditions, as well as for athletes desiring to build and/or maintain muscle mass and improve muscle strength. The invention may also provide a nutritional means to decrease mental fatigue. In one embodiment, compositions of the invention may be provided as tablets, caplets, gelatin capsules, chewable tablets, a supplemented drink, nutrition bar, or other formulation to provide at least one BCAA/mineral chelate to an individual to decrease mental fatigue following, for example, strenuous exercise or physically- demanding work. BCAA/mineral chelates of the invention may also be administered in a method of the invention to increase BCAA absorption and decrease central fatigue after exercise.
[025] Table 1 lists ingredients comprising an example of a composition comprising a powdered formulation to provide a nutritional drink as provided by the invention.
Table 1
Amount Protein Fat Carb Leucine Total lngedient (g) (g) (g) (g) (g) BCAA
WPC 80 8.34 6.51 0.75 0.33 0.72 1.48
WPI 4.02 3.51 3.02 0.03 0.39 0.85
Chelated leucine 0.48 0.40 0.63
Crystalline Fructose 17.00
Carageennan 1.00
Brazilian Cocoa Powder 1.50
Color 0.03
Salt 0.06
Milk Flavor 1.70
Chocolate Malt Flavor 1.50
Vanilla Flavor 1.00
Total 36.68 10.02 3.77 0.36 1.51 2.95 percent of protein 15.03 29.48
2 times per day consumption 73.37 20.04 7.53 0.72 3.01 5.91
[026] In a formulation such as that shown in Table 1 above, it is understood that ingredient quantities and ratios may be varied significantly yet still provide a formulation that will be easily dispersed in water. WPC (whey protein concentrate), for example, may be present in such a formulation from about 5 grams to about 10 grams. Whey protein isolate (WPI) may be present from about 1 gram to about 7 grams. Chelated leucine may be present in such a composition from about 0.1 gram to about 2 grams, and crystalline fructose may be present from about 10 grams to about 20 grams.
[027] Compositions of the invention may comprise at least about about 0.1 grams of leucine, isoleucine, valine, or combinations thereof, and preferably will be formulated to provide at least about 3 grams daily of leucine, isoleucine, valine, or combinations thereof. Compositions may be provided for occasional or for regular use, with regular use being preferred. Regular use may include daily, twice-daily, every other day, or other regimens, for example. For improved effect, administration of at least 3 grams of leucine per day, for example, may be preferred. Compositions of the invention, providing, for example, BCAA/mineral chelates for use in aqueous formulations, powders dispersed in aqueous formulations, or similar compositions, increase availability of BCAAs to human or animal subjects to whom they are provided or administered. Also disclosed is a method for providing branched-chain amino acids in a liquid beverage, the method comprising forming a branched-chain amino acid chelate and adding the chelate to the beverage. [028] The invention may be further described by means of the following non-limiting examples.
Examples
[029] The inventors attempted to incorporate free leucine and microencapsulated free leucine into beverages and found both products difficult to use and difficult to disperse. The microencapsulated leucine produced a turbid, cloudy solution, indicative of non-dissolving particulates. Free leucine showed a separation phenomenon in aqueous solution. When a BCAA/mineral chelate of the invention was utilized, however, the chelated leucine product was much more easily dispersed and did not separate or increase turbidity of aqueous systems.
Sample Calcium Leucinate Formulation
[030] To form calcium leucinate, 26.2 grams of l-leucine (Seltzer Ingredients, Carlsbad, California) were dispersed in 75 ml deionized water. While stirring, 8 grams of sodium hydroxide were added. The solution was heated to approximately 42 degrees C to dissolve the leucine. In a separate container, 11.1 grams of calcium chloride (Chris Hansen) were dissolved in 25 ml deionized water. While stirring the leucine solution, the calcium chloride solution was added. A voluminous white precipitate was formed. The precipitated calcium-leucine chelate was separated, washed and dried.

Claims

What is claimed is:
1. A composition comprising a chelate comprising a mineral and a branched-chain amino acid, wherein the mineral is a mono- or di-valent cation.
2. The composition of claim 1 wherein the mineral is chosen from the group consisting of calcium, magnesium, potassium, and zinc.
3. The composition of claim 1 wherein the branched-chain amino acid is chosen from the group consisting of leucine, isoleucine, and valine.
4. The composition of claim 1 wherein the amino acid comprises from about 75 to about 80 percent by weight and the mineral comprises from about 20 to about 25% percent.
5. The composition of claim 1 wherein the amino acid comprises from about 40 to about 90 percent by weight and the mineral comprises from about 5 to about 60 percent.
6. The composition of claim 1 wherein the amino acid comprises from about 60 to about 90 percent by weight and the mineral comprises from about
10 to about 40 percent.
7. The composition of claim 1 further comprising a whey protein isolate or whey protein concentrate.
8. A method for decreasing mental fatigue in a human comprising administering at least one branched-chain amino acid/mineral chelate to the human.
9. The method of claim 8 wherein the mineral is chosen from the group consisting of calcium, magnesium, potassium, and zinc.
10. A method for increasing or maintaining muscle mass in a human or animal subject, the method comprising administering to the human or animal a therapeutically effective amount of a composition comprising at least one branched-chain amino acid/mineral chelate.
11. The method of claim 10 wherein the mineral is chosen from the group consisting of calcium, magnesium, potassium, and zinc.
12. The method of claim 10 wherein the branched-chain amino acid is chosen from the group consisting of leucine, isoleucine, and valine.
13. The method of claim 10 wherein the amino acid comprises from about 75 to about 80 percent by weight and the mineral comprises from about 20 to about 25 percent.
14. The method of claim 10 wherein the amino acid comprises from about 40 to about 90 percent by weight and the mineral comprises from about 5 to about 60 percent.
15. The method of claim 10 wherein the amino acid comprises from about 60 to about 90 percent and the mineral comprises from about 10 to about 40 percent.
PCT/US2008/050974 2007-01-14 2008-01-14 Branched chain amino acid chelate Ceased WO2008086538A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88489007P 2007-01-14 2007-01-14
US60/884,890 2007-01-14

Publications (1)

Publication Number Publication Date
WO2008086538A1 true WO2008086538A1 (en) 2008-07-17

Family

ID=39609084

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/050974 Ceased WO2008086538A1 (en) 2007-01-14 2008-01-14 Branched chain amino acid chelate

Country Status (1)

Country Link
WO (1) WO2008086538A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865382B1 (en) 2009-12-24 2018-01-17 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
EP2768322B1 (en) 2011-10-21 2018-05-30 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
RU2686086C1 (en) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Method for correction of pre-sarcopenia or sarcopenia correction in a patient with adequate consumption of essential nutrients receiving programmed hemodialysis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299914B1 (en) * 1999-11-01 2001-10-09 Albion International, Inc. Compositions and methods for calcium fortification of dairy products and oleaginous foods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6299914B1 (en) * 1999-11-01 2001-10-09 Albion International, Inc. Compositions and methods for calcium fortification of dairy products and oleaginous foods

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865382B1 (en) 2009-12-24 2018-01-17 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
EP2768322B1 (en) 2011-10-21 2018-05-30 Nestec S.A. Whey protein micelles against muscle atrophy and sarcopenia
RU2686086C1 (en) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Method for correction of pre-sarcopenia or sarcopenia correction in a patient with adequate consumption of essential nutrients receiving programmed hemodialysis

Similar Documents

Publication Publication Date Title
AU774654B2 (en) Bioavailable chelates of creatine and essential metals
EP1536781B1 (en) Nutritional or pharmaceutical compositions for increasing the creatine response of organisms
Flodin The metabolic roles, pharmacology, and toxicology of lysine.
CA2645178C (en) Mixed amino acid mineral chelates and compositions having improved solubility
CN108024981B (en) A kind of carboxylic acid composition for treating patients with nephropathy
US6667063B2 (en) Nutritional or therapeutic supplement and method
JP2024122087A (en) Free amino acid absorption enhancer and method for enhancing absorption of free amino acids
CN101528066A (en) Long-term feed - cancer patient
US6294207B1 (en) Calcium fortification of oleaginous foods
EP3184107A1 (en) Method and preparation for treating metabolic stress
US20090042770A1 (en) Branched Chain Amino Acid Chelate
CN101166429A (en) Alimentation composition
JP2002065212A (en) Food composition for strengthening muscle, and muscle- strengthening agent
WO2007069072A2 (en) Salts of mineral nutrients stabilized with amino acids and/or ammonium salts, products and food supplements that contain them and methods for obtaining same
WO2008086538A1 (en) Branched chain amino acid chelate
ES2295223T3 (en) ALFA-CETOGLUTARATES OF ACTIVE PRINCIPLES AND COMPOSITIONS THAT CONTAIN THEM.
US20040048925A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
RU2255604C2 (en) Biologically active food additive preventing calcium deficiency and optimizing calcium metabolism, and food product containing thereof
US20040220266A1 (en) Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
CN101402583B (en) Levorotation carnitine acid calcium phosphate, preparation method and use thereof
US11970435B2 (en) Taste-modified creatine salts, compounds, compositions and uses thereof
JPH0515339A (en) Protein-like composition, nourishing medicine for serious stress and nourishing medicine for hepatic disease
JPS595111A (en) Nutritional preparation for infants with phenylketonuria
JP2010095474A (en) Calcium absorption-promoting composition and calcium absorption-promoting food and drink
US20190175533A1 (en) Nutritional supplement for improved calcium absorption

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727633

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009545722

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08727633

Country of ref document: EP

Kind code of ref document: A1